- Home
- AGEN vs JYNT Comparison
AGEN vs JYNT Comparison
Compare AGEN & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGEN | JYNT |
|---|---|---|
| Founded | 1994 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Multi-Sector Companies |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 138.0M |
| IPO Year | 1999 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AGEN | JYNT |
|---|---|---|
| Price | $2.98 | $8.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $14.50 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 381.7K | 44.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.37 | 0.12 |
| Revenue | $42,877,086.00 | ★ $117,696,356.00 |
| Revenue This Year | $5.19 | $5.65 |
| Revenue Next Year | $68.25 | $3.86 |
| P/E Ratio | ★ $7.88 | $72.50 |
| Revenue Growth | ★ 89.95 | 15.49 |
| 52 Week Low | $1.38 | $7.50 |
| 52 Week High | $7.34 | $13.47 |
Technical Indicators
Market Signals| Indicator | AGEN | JYNT |
|---|---|---|
| Relative Strength Index (RSI) | 43.35 | 40.90 |
| Support Level | $2.90 | $8.56 |
| Resistance Level | $3.15 | $8.77 |
| Average True Range (ATR) | 0.18 | 0.39 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 15.79 | 38.21 |
Price Performance
Historical ComparisonAbout AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.